PLX Protalix BioTherapeutics Inc. (DE)

0.39
-0.01  -2%
Previous Close 0.4
Open 0.4
Price To Book -0.89
Market Cap 58014594
Shares 148,374,921
Volume 661,297
Short Ratio 9.85
Av. Daily Volume 531,127

NewsSee all news

  1. Protalix (PLX) Reports Q3 Loss, Lags Revenue Estimates
  2. Protalix: 3Q Earnings Snapshot
  3. Protalix BioTherapeutics Reports 2018 Third Quarter Results and Provides Corporate Update
  4. Will Protalix (PLX) Report Negative Earnings Next Week? What You Should Know
  5. Protalix BioTherapeutics to Hold Third Quarter 2018 Financial Results and Corporate Update Conference Call on November 7, 2018

SEC filingsSee all SEC filings

  1. 8-K - Current report 181233586
  2. CT ORDER - Confidential treatment order 181215692
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181166776
  4. 8-K - Current report 181164680
  5. DEF 14A - Other definitive proxy statements 181126668

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved May 1, 2012.
Taliglucerase alfa
Gaucher disease
Phase 3 dosing commenced October 2016. Enrollment to be finalized 2018.
Pegunigalsidase alfa (PRX-102)
Fabry disease
Phase 2 interim data released January 3, 2017. Full data released April 12, 2017. Company noted data were positive but results showed efficacy down on January data.
AIR DNase (PRX-110)
Cystic Fibrosis
Phase 2 data released March 13, 2018 - key endpoints met. Data presented at DDW Meeting - 67% of patients experienced a clinical response.
OPRX-106
Ulcerative Colitis
Phase 3 enrollment to be completed 4Q 2018.
Pegunigalsidase alfa (PRX-102) BRIDGE
Fabry disease

Latest News

  1. Protalix (PLX) Reports Q3 Loss, Lags Revenue Estimates
  2. Protalix: 3Q Earnings Snapshot
  3. Protalix BioTherapeutics Reports 2018 Third Quarter Results and Provides Corporate Update
  4. Will Protalix (PLX) Report Negative Earnings Next Week? What You Should Know
  5. Protalix BioTherapeutics to Hold Third Quarter 2018 Financial Results and Corporate Update Conference Call on November 7, 2018
  6. New Research: Key Drivers of Growth for Cenovus Energy, Protalix BioTherapeutics, Rayonier Advanced Materials, B2Gold, Match Group, and Qudian Inc. Sponsored ADR — Factors of Influence, Major Initiatives and Sustained Production
  7. The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker
  8. Protalix BioTherapeutics Presents Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 1st Canadian Symposium on Lysosomal Diseases 2018
  9. The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs
  10. Today’s Research Reports on Stocks to Watch: GTx and Protalix BioTherapeutics
  11. Protalix BioTherapeutics Reports Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease
  12. Protalix BioTherapeutics to Present Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 1st Canadian Symposium on Lysosomal Diseases 2018
  13. Protalix (PLX) Reports Q2 Loss, Misses Revenue Estimates
  14. Who Owns Protalix BioTherapeutics Inc (NYSEMKT:PLX)?
  15. Protalix Biotherapeutics, Inc. to Host Earnings Call

SEC Filings

  1. 8-K - Current report 181233586
  2. CT ORDER - Confidential treatment order 181215692
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181166776
  4. 8-K - Current report 181164680
  5. DEF 14A - Other definitive proxy statements 181126668
  6. PRE 14A - Other preliminary proxy statements 181111281
  7. 8-K - Current report 181109269
  8. 8-K - Current report 181080871
  9. 8-K - Current report 181010246
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 181005104